Sangamo strikes brain-targeting AAV partnership with Astellas
Sangamo has made another gene therapy deal to keep the lights on for a few more months, extending its funding by another three months until at least mid-2025. On Thursday, the struggling California...
View ArticleRoche’s Parkinson’s drug flunks second mid-stage trial
Roche’s alpha-synuclein-targeting antibody has failed to slow the progression of motor symptoms in a mid-stage Parkinson’s disease test, marking the latest setback in a largely challenging year for the...
View ArticleEx-Color Health execs raise $10M to bring AI to pharma
Employees Nos. 1 and 2 of the $4.6 billion health tech startup Color Health have started their own company, aiming to tackle pharma's regulatory burden with generative AI. The San Francisco-based...
View ArticleVertex’s non-opioid pill disappoints in mid-stage chronic pain study
Vertex Pharmaceuticals announced highly anticipated results from a Phase 2 trial Thursday morning in a chronic pain condition, saying its non-opioid pain pill suzetrigine met the primary endpoint and...
View ArticleEndpoints winners and losers 2024: Best and worst biotech trends
Last year’s Endpoints News winners and losers list was such a hit that we decided to make it a tradition. As always, we’re keeping track of who’s ⬆️ and who’s ⬇️ in biopharma, the ideas ...
View ArticleHealth tech industry predicts cautious funding optimism in 2025
After a tough few years, healthcare startups are entering 2025 with cautious optimism. Twelve months ago, early-stage startups faced a funding cliff. Many didn’t survive: Across industries, more...
View ArticleSorriso claims a Phase 1b success for oral antibody in ulcerative colitis
A private startup from Salt Lake City aiming to develop oral antibodies says it has succeeded in an early trial, a potentially significant scientific advancement in a world where systemic treatments...
View ArticleBristol Myers pays $100M upfront to collaborate with Leqembi originator in...
Bristol Myers Squibb is partnering with the original developer of Leqembi in a new Alzheimer’s disease deal. The large drugmaker said Thursday that it's giving BioArctic $100 million upfront to license...
View ArticleLonza expands capsule footprint; BioCentriq's new HQ
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lonza is expanding its manufacturing sites in ...
View ArticleIn blow to compounders, FDA reaffirms tirzepatide shortage is over
The FDA has reaffirmed that the shortage of Eli Lilly’s blockbuster obesity and diabetes medications is resolved, dealing a blow to pharmacies and telehealth services that have capitalized on providing...
View ArticleGilead deepens its stake in Assembly Biosciences; NGM licenses out MASH drug
Plus, news about Abilita Therapeutics, Orion, Novartis, XGEN Venture, Palleon, Henlius, TigaTx, HERVolution Therapeutics and Krystal Biotech: Gilead now owns 30% of Assembly Biosciences: The drugmaker...
View ArticleWhat health tech startups can expect in 2025
This week, Shelby and I looked at the state of health tech funding as we head into next year. In our conversations with investors and bankers, we found some cautious ...
View ArticleRegeneron forges ahead in factor XI despite field’s mixed results
Regeneron will start a “broad” Phase 3 program next year for its two factor XI antibodies, following open-label Phase 2 results for the experimental anti-clotting drugs. The company
View ArticlePayers generally meet drug price watchdog's 'fair access' standards, report says
The Institute for Clinical and Economic Review said major insurers’ drug coverage policies generally do align with the pricing watchdog's set of "fair access" standards, according to a report released...
View ArticleMesoblast wins long-awaited approval for cell therapy
Mesoblast’s stock surged on Thursday after the company won FDA approval for its twice-rejected graft-versus-host disease therapy. Remestemcel-L is the first mesenchymal stromal cell therapy to be...
View ArticleXcovery nabs first FDA approval for lung cancer drug
The FDA has approved Xcovery Holdings' ALK inhibitor Ensacove for first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung...
View ArticleFDA rejects Zealand Pharma's short bowel syndrome drug
The FDA rejected Zealand Pharma’s short bowel syndrome drug, and asked the company to run another trial before it reconsiders. The FDA told Zealand it wanted an additional test to “provide further...
View ArticleFDA approves Ionis’ treatment for a rare metabolic disorder
Ionis’ antisense oligonucleotide olezarsen is now the first approved treatment for familial chylomicronemia syndrome, a rare metabolic disorder that prevents the body from breaking down fats called...
View ArticleNovo’s 23% weight loss with CagriSema falls short of high expectations
Novo Nordisk said its highly anticipated Phase 3 readout showed that CagriSema only managed 22.7% weight loss, failing to hit the 25% benchmark the company, investors and analysts were seeking. The...
View ArticleFlorida cancer biotech Syncromune raises $100M Series A
Syncromune, a biotech startup working on combination immunotherapies, has put together a $100 million Series A, the company told Endpoints News. The round was led by a new, undisclosed institutional...
View ArticleAadi starts from scratch as it sells assets, licenses ADCs and raises new funds
In a major reset to round off the year, Aadi Bioscience is divesting its only marketed product and in-licensing a trio of ADCs developed by WuXi Biologics and another Chinese biotech. Aadi has inked an...
View ArticleDaiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney...
→ Yuki Abe will step in to replace the late Toshinori Agatsuma on Jan. 1 as head of the R&D division at Daiichi Sankyo and VP of its ...
View ArticleTracer Biotechnologies raises $10M, partners with AstraZeneca
Tracer Biotechnologies has raised a $10 million Series A round to advance its technology that's designed to monitor circulating tumor DNA in cancer patients over lengthy periods. The company uses...
View ArticleCommure's latest acquisition sends follow up texts to patients
General Catalyst-backed Commure is buying another General Catalyst-backed startup that sends follow-up texts to patients. Commure, which was valued at over $6 billion after merging with General...
View Article